ASP-2905 – (792184-90-8)

ASP2905 is a potent and selective inhibitor of the potassium voltage-gated channel subfamily H member 3 (KCNH3), also known as Kv12.2.

ASP2905 has shown potential in crossing the blood-brain barrier and exhibits antipsychotic and cognitive-enhancing activities. Preclinical studies indicate that ASP2905 can improve attention and reduce hyperactivity in animal models, suggesting its potential use in treating attention deficit hyperactivity disorder (ADHD).

The compound has also been shown to modulate neurotransmitter activity, particularly dopamine and acetylcholine, in the prefrontal cortex, further supporting its therapeutic potential. ASP2905 is currently under investigation for its pharmacological effects and potential clinical applications.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://pubchem.ncbi.nlm.nih.gov/compound/46913817
https://www.medchemexpress.com/asp2905.html
https://www.medkoo.com/products/33804
https://pubmed.ncbi.nlm.nih.gov/30462746/